522 related articles for article (PubMed ID: 16035083)
21. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
22. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
Yurci A; Kalkan AO; Ozbakir O; Karaman A; Torun E; Kula M; Baskol M; Gursoy S; Yucesoy M; Bayram F
Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1206-12. PubMed ID: 21971374
[TBL] [Abstract][Full Text] [Related]
24. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
Sawka AM; Ioannidis G; Papaioannou A; Thabane L; Olszynski WP; Brown JP; Hanley DA; Murray TM; Josse RG; Sebaldt RJ; Petrie A; Tenenhouse A; Goldsmith CH; Boulos P; Kouroukis T; Adachi JD
J Obstet Gynaecol Can; 2005 Aug; 27(8):759-64. PubMed ID: 16287007
[TBL] [Abstract][Full Text] [Related]
25. Alendronate in kidney transplant patients: a single-center experience.
Toro J; Gentil MA; García R; Pérez-Valdivia MA; García Avellano E; Algarra GR; Pereira P; González-Roncero F; Mateos J
Transplant Proc; 2005 Apr; 37(3):1471-2. PubMed ID: 15866643
[TBL] [Abstract][Full Text] [Related]
26. Prevention of early loss of bone mineral density after liver transplantation by prostaglandin E1.
Hommann M; Kämmerer D; Lehmann G; Kornberg A; Küpper B; Daffner W; Wolf G; Settmacher U
Transplant Proc; 2007 Mar; 39(2):540-3. PubMed ID: 17362777
[TBL] [Abstract][Full Text] [Related]
27. Effect of alendronate on bone mineral density in adult patients with Laron syndrome (primary growth hormone insensitivity).
Eshed V; Benbassat CA; Laron Z
Growth Horm IGF Res; 2006 Apr; 16(2):119-24. PubMed ID: 16617031
[TBL] [Abstract][Full Text] [Related]
28. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study.
Benetti A; Crosignani A; Varenna M; Giussani CS; Allocca M; Zuin M; Podda M; Battezzati PM
J Clin Gastroenterol; 2008 Mar; 42(3):306-11. PubMed ID: 18223492
[TBL] [Abstract][Full Text] [Related]
29. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000
[TBL] [Abstract][Full Text] [Related]
30. Serial measurements of bone density at the lumbar spine do not predict fracture risk after liver transplantation.
Hardinger KL; Ho B; Schnitzler MA; Desai N; Lowell J; Shenoy S; Chapman W; Crippin JS
Liver Transpl; 2003 Aug; 9(8):857-62. PubMed ID: 12884200
[TBL] [Abstract][Full Text] [Related]
31. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
32. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus.
Yeap SS; Fauzi AR; Kong NC; Halim AG; Soehardy Z; Rahimah I; Chow SK; Goh EM
J Rheumatol; 2008 Dec; 35(12):2344-7. PubMed ID: 19004038
[TBL] [Abstract][Full Text] [Related]
33. Assessment of serial changes of bone mineral density at lumbar spine and femoral neck before and after liver transplantation.
Xu H; Eichstaedt H
Chin Med J (Engl); 1999 Apr; 112(4):379-81. PubMed ID: 11593545
[TBL] [Abstract][Full Text] [Related]
34. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
35. Changes in bone mineral density and selected metabolic parameters over 24 months following renal transplantation.
Al-Gabri S; Zadrazil J; Krejcí K; Horák P; Bachleda P
Transplant Proc; 2005 Mar; 37(2):1014-9. PubMed ID: 15848609
[TBL] [Abstract][Full Text] [Related]
36. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
37. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
38. Bone disease in patients awaiting liver transplantation. Has the situation improved in the last two decades?
Monegal A; Navasa M; Peris P; Colmenero J; Cuervo A; Muxí A; Gifre L; Guañabens N
Calcif Tissue Int; 2013 Dec; 93(6):571-6. PubMed ID: 24065305
[TBL] [Abstract][Full Text] [Related]
39. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation.
Atamaz F; Hepguler S; Akyildiz M; Karasu Z; Kilic M
Osteoporos Int; 2006; 17(6):942-9. PubMed ID: 16550299
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study.
Bianchi ML; Cimaz R; Bardare M; Zulian F; Lepore L; Boncompagni A; Galbiati E; Corona F; Luisetto G; Giuntini D; Picco P; Brandi ML; Falcini F
Arthritis Rheum; 2000 Sep; 43(9):1960-6. PubMed ID: 11014345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
